A Pilot Study to Assess the Efficacy of Linagliptin as an Adjunct in Schizophrenia Patients
Phase of Trial: Phase I
Latest Information Update: 22 Apr 2019
Price : $35 *
At a glance
- Drugs Linagliptin (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 14 Aug 2018 Status changed from suspended to discontinued.
- 23 Sep 2016 Planned End Date changed from 1 Jul 2016 to 1 Aug 2018.